Bladder cancer and its signs and symptoms
Our understanding of the molecular mechanisms of tumour development and how tumours spread has continually improved, leading to major breakthroughs that have transformed several aspects of cancer care. Roche’s scientists are pioneers in cancer research, and they continuously investigate innovative and personalised treatment options.
Explore the latest in Roche's research and developments in oncology.
This analysis from IMvigor130, a randomized phase III study of ▼atezolizumab with or without chemo in patients with previously untreated mUC, investigated the influence of primary tumor site on clinical outcomes. Efficacy and safety in subgroups with lower or upper tract UC are reported.
The MORPHEUS platform is comprised of multiple global, open-label, randomized Phase Ib/II trials designed to capture early efficacy signals and evaluate the safety of treatment combinations in patients with different cancers. The MORPHEUS-mUC study is evaluating multiple ▼atezolizumab combination regimens compared with ▼atezolizumab monotherapy in patients with previously platinum treated mUC.
This post-hoc analysis from SAUL, a single-arm phase IIIb study of single-agent ▼atezolizumab in patients with mUC, investigated clinical outcomes according to the primary tumor site. Efficacy and safety are reported in bladder or upper tract disease subgroups.
This study evaluated the first-line treatment distribution observed in a real-world population of patients with hepatocellular carcinoma and the median overall survival estimates for these systemic therapies from 2011 to 2018 in the United States.
Supplementary figures for the phase Ib/II open-label, randomized evaluation of 2L ▼atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC)
The MORPHEUS platform is comprised of multiple global, open-label, randomized Phase Ib/II trials designed to capture early efficacy signals and evaluate the safety of treatment combinations in patients with different cancers. This study evaluated the efficacy and safety of ▼atezolizumab plus BL-8040 in patients with pancreatic ductal adenocarcinoma and gastric cancer.
Rowan Chlebowski outlines the findings from the Women's Health Initiative trials investigating the effect of oestrogen, either alone or with progestin, on breast cancer risk, and puts them in context of recent opposing data.
Sara Tolaney takes us through the ATEMPT adjuvant therapy trial comparing trastuzumab emtansine with trastuzumab plus paclitaxel in patients with stage I HER2-positive breast cancer.
The second daily report from SABCS 2019. Today’s sessions explored the role of radiotherapy combined with immunotherapy in oligometastatic cancer, along with the role of proteogenomics in precision medicine for breast cancer. An additional session looked at the future of immuno-oncology in breast cancer.
A drug- and indication-specific module for the Kaiku digital patient monitoring (DPM) platform was co-developed with patients and healthcare professionals (HCPs) for cancer immunotherapy-treated patients with advanced/metastatic non-small cell lung cancer. A pilot study was conducted to assess user experience, overall satisfaction and the impact of the DPM tool on clinical care. This poster reports results from patient and HCP surveys, as well as HCP interviews, over a minimum of three months of DPM tool use.
This retrospective observational study evaluated the association of baseline corticosteroid use with overall survival in patients receiving cancer immunotherapy for advanced or metastatic melanoma, non-small cell lung cancer or urothelial carcinoma in US clinical practice.
IMpower110 is a randomized, Phase III study of atezolizumab monotherapy vs platinum-based chemotherapy in PD-L1–selected, chemo-naive patients with metastatic NSCLC. Efficacy analyses in key pre-specified subgroups in IMpower110, defined by the 22C3 and SP263 PD-L1 IHC and bTMB assays are reported
This poster describes the safety and preliminary efficacy of first-line atezolizumab monotherapy in a cohort of patients with locally advanced or metastatic melanoma whose tumors had wild-type BRAF at codon 600. In addition to safety, this reports the objective response rate, duration of response and progression-free survival for these patients (Cohort C of CO39721: NCT03178851).
This poster describes real world treatment patterns for CNS metastases and survival outcomes in melanoma patients with metastatic disease using data from the Flatiron Health database
This final report of the of the phase 3 coBRIM study reports the safety and clinical benefit of cobimetinib plus vemurafenib versus vemurafenib alone in patients with advanced BRAFV600-mutated melanoma after an extended follow-up.